Correlation Between Organon and Bristol-Myers Squibb

Can any of the company-specific risk be diversified away by investing in both Organon and Bristol-Myers Squibb at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Organon and Bristol-Myers Squibb into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Organon Co and Bristol Myers Squibb, you can compare the effects of market volatilities on Organon and Bristol-Myers Squibb and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Organon with a short position of Bristol-Myers Squibb. Check out your portfolio center. Please also check ongoing floating volatility patterns of Organon and Bristol-Myers Squibb.

Diversification Opportunities for Organon and Bristol-Myers Squibb

0.37

Correlation Coefficient

Organon  Bristol-Myers Squibb

Weak diversification

The 3 months correlation between Organon and Bristol-Myers is 0.37. Overlapping area represents the amount of risk that can be diversified away by holding Organon Co and Bristol Myers Squibb in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myers Squibb and Organon is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Organon Co are associated (or correlated) with Bristol-Myers Squibb. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myers Squibb has no effect on the direction of Organon i.e., Organon and Bristol-Myers Squibb go up and down completely randomly.

Pair Corralation between Organon and Bristol-Myers Squibb

Considering the 90-day investment horizon Organon is expected to generate 6.63 times less return on investment than Bristol-Myers Squibb. But when comparing it to its historical volatility, Organon Co is 1.44 times less risky than Bristol-Myers Squibb. It trades about 0.01 of its potential returns per unit of risk. Bristol Myers Squibb is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  93,474  in Bristol Myers Squibb on December 28, 2024 and sell it today you would earn a total of  6,526  from holding Bristol Myers Squibb or generate 6.98% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	62.3%
Values	Daily Returns

Organon Co  vs.  Bristol Myers Squibb

Organon

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Organon Co are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy technical and fundamental indicators, Organon is not utilizing all of its potentials. The new stock price disarray, may contribute to short-term losses for the investors.

Bristol Myers Squibb

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile primary indicators, Bristol-Myers Squibb reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Organon and Bristol-Myers Squibb

The main advantage of trading using opposite Organon and Bristol-Myers Squibb positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Organon position performs unexpectedly, Bristol-Myers Squibb can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will offset losses from the drop in Bristol-Myers Squibb's long position.

The idea behind Organon Co and Bristol Myers Squibb pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.